This clinical trial is focused on studying the effects of a medication called dapirolizumab pegol in people with systemic lupus erythematosus (SLE)</b), a condition where the immune system attacks the body's own tissues, causing inflammation and damage. The study aims to determine if dapirolizumab pegol, when added to standard treatments, can help improve the symptoms of moderate to severe SLE. Participants in the study will receive either dapirolizumab pegol or a placebo, which looks like the medication but does not contain the active substance.
The study will take place over a period of time, during which participants will receive the treatment through an infusion, which means the medication is given directly into a vein. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The goal is to see if the medication can provide a long-term improvement in the disease activity of SLE.
In addition to dapirolizumab pegol, participants will continue their usual standard of care treatments, which may include medications like antimalarials, corticosteroids, and immunosuppressants. These are commonly used to manage SLE symptoms. The study will help researchers understand if adding dapirolizumab pegol to these treatments can offer additional benefits for people living with SLE.
Belgium 
Denmark 
France 
Germany 
Greece 
Italy 
Poland 
Spain 
The Netherlands 
